Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A dec exp |
| Therapy | Buthionine sulfoximine |
| Indication/Tumor Type | ovarian cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A dec exp | ovarian cancer | predicted - sensitive | Buthionine sulfoximine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770). | 30686770 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30686770) | Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. | Full reference... |